For patients weighing at least 50kg, Injectafer may be administered as a single dose option of 15mg/kg body weight up to a maximum of 1000mg intravenously.
Vadadustat and darbepoetin alfa had similar hematologic efficacy in patients with nondialysis-dependent CKD (NDD-CKD) and those on dialysis, but vadadustat was associated with a higher risk of major adverse cardiovascular events in patients with NDD-CKD.
Circulating FGF23 starts to rise in early stage CKD before the development of other abnormalities such as high parathyroid and phosphate levels and low calcium and 1,25(OH)2D levels.
An analysis of contemporary ESA utilization among patients with anemia of nondialysis-dependent chronic kidney disease may help identify optimal candidates for treatment.
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.
Comorbidities and advanced CKD were prevalent among the approximately 275,000 patients with anemia of CKD from the international DISCOVER CKD cohort.
Early detection of iron status may improve cardiovascular risk assessment in patients with CKD, according to investigators.
Investigators sought to define an ESA dosing regimen that reduces the likelihood of transfusion while minimizing any potential cardiovascular risks.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Percentage of donations with antibodies has risen steadily over time, according to the Red Cross